Literature DB >> 34978090

Transient depletion of T cells during COVID-19 and seasonal influenza in people living with HIV.

Eisuke Adachi1, Makoto Saito2, Hiroyuki Nagai1, Kazuhiko Ikeuchi1, Michiko Koga1, Takeya Tsutsumi2, Hiroshi Yotsuyanagi2.   

Abstract

Entities:  

Keywords:  SARS coronavirus; helper T cell; human immunodeficiency virus; immune responses; influenza virus; virus classification

Mesh:

Year:  2022        PMID: 34978090      PMCID: PMC9015586          DOI: 10.1002/jmv.27543

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
To the editor, The cellular immune deficiency seen in people living with HIV (PLWH) is of potential concern as dysfunctional immune responses contribute to disease progression and dysregulated T cell responses can result in immunopathology. , Transient decrease in lymphocytes during COVID‐19 is well known and a preexisting T cell depletion induced by HIV may cause deleterious clinical consequences. Additionally, seasonal influenza has been compared with COVID‐19 given the common features shared by these viruses, such as fever and respiratory symptoms that range from mild forms to severe pneumonia, whereas these two viruses differ in their receptors for infection and the duration and incubation period of the disease they cause. T cell responses could affect both the initial nonspecific innate immune response and the following antigen‐specific adaptive immunity, which is mediated by humoral immunity and T cells including CD8+, CD4+ and regulatory T cells. In this study, we investigated the changes in T cell subset composition, such as CD4+ cell count and CD8+ cell count, during seasonal influenza infection and COVID‐19 among PLWH. We conducted a retrospective analysis of the routine clinical records of PLWH at an HIV/AIDS referral hospital in Tokyo, Japan. PLWH with COVID‐19 confirmed by reverse transcription polymerase chain reaction between March 2020 and September 2021 or PLWH with laboratory‐confirmed seasonal Influenza between April 2010 and April 2019 were included. T cell subset were assessed at three time points: within 3 months before symptom onset, within 10 days postsymptom onset, and within 1–6 months after recovery. To examine the transient changes in the T cell count before and after infection and to exclude changes due to other factors, we included only PLWH who had been on effective antiretroviral therapy for at least 1 year and who had the results of T cell subset at all of the three time points above. We used the repeated measures analysis of variance to compare the three time points and the paired t‐test were used to evaluate the difference between cell counts before symptom onset and during illness. Statistical significance was defined as two‐sided p values < 0.05. As shown in Table 1, there were significant changes in the transition of T cell counts in both influenza infection and COVID‐19. A total of 17 COVID‐19 patients was eligible; all were inpatients, and seven patients were with moderate or higher disease. Sixteen patients were male the median age was 53 years (range: 26–68). The mean CD4+ cell count was 659 cells/μl, 436 cells/μl, and 686 cells/μl (before onset, during infection and after recovery, respectively) (before onset vs. during infection: p = 0.0001, Figure 1A), CD8+ T cell count was 805 cells/μl, 539 cells/μl, and 831 cells/μl (before onset vs. during infection: p = 0.0026, Figure 1B), and CD4+/CD8+ ratio was 0.94, 0.870, and 0.96 (before onset vs. during infection: p = 0.182, Figure 1C). The mean lymphocyte count was 2148 cells/μl, 1505 cells/μl, and 2066 cells/μl (before onset vs. during infection: p = 0.0003). There was no significant change in CD4+ cell, CD8+ cell, and total lymphocyte counts between those before symptom onset and after recovery.
Table 1

The transition of T cell count in COVID‐19 and seasonal influenza virus infection

COVID‐19seasonal influenza
Before onsetDuring infectionAfter recovery p valuea Before onsetDuring infectionAfter recovery p valuea
Lymphocyte (μ/L)2148150520660.00031884136918250.0001
CD4+(μ/L)659436686<0.0001455316445<0.0001
CD8+(μ/L)8055398310.017965807580.002
CD4+/CD8+ ratio0.940.870.960.240.650.650.670.65

Abbreviation: ANOVA, analysis of variance.

p values were calculated using repeated measures ANOVA.

Figure 1

Temporal changes in the T‐cell subset composition in peopele living with HIV. (A) CD4+ cell count in COVID‐19, (B) CD8+ cell count in COVID‐19, (C) CD4+/CD8+ ratio in COVID‐19, (D) CD4+ cell count in seasonal influenza, (E) CD8+ cell count in easonal influenza, (F) CD4+/CD8+ ratio in seasonal influenza. Three time points were as follows, before onset: within 3 months before symptom onset, during infection: within 10 days postsymptom onset, after recovery: within 1–6 months after recovery. The paired t‐test were used to evaluate the difference between cell counts before onset and during infection. *Statistical significance was defined as two‐sided p < 0.05

The transition of T cell count in COVID‐19 and seasonal influenza virus infection Abbreviation: ANOVA, analysis of variance. p values were calculated using repeated measures ANOVA. Temporal changes in the T‐cell subset composition in peopele living with HIV. (A) CD4+ cell count in COVID‐19, (B) CD8+ cell count in COVID‐19, (C) CD4+/CD8+ ratio in COVID‐19, (D) CD4+ cell count in seasonal influenza, (E) CD8+ cell count in easonal influenza, (F) CD4+/CD8+ ratio in seasonal influenza. Three time points were as follows, before onset: within 3 months before symptom onset, during infection: within 10 days postsymptom onset, after recovery: within 1–6 months after recovery. The paired t‐test were used to evaluate the difference between cell counts before onset and during infection. *Statistical significance was defined as two‐sided p < 0.05 Next, we analyzed a total of 27 Influenza infections; there were no hospitalizations, and no patients had pneumonia or encephalopathy. All patients were male, and the median age was 39.5 years (range: 19–54). The mean CD4+ cell count was 455 cells/μl, 316 cells/μl, and 445 cells/μl (before onset vs. during infection: p < 0.0001, Figure 1D). CD8+ cell count was 796 cells/μl, 580 cells/μl, and 758 cells/μl (before onset vs. during infection: p = 0.0033, Figure 1E), and CD4+/CD8+ ratio was 0.65, 0.65, and 067 (before onset vs. during infection: p = 0.932, Figure 1F). The mean lymphocyte count in seasonal influenza patients was 1884 cells/μl, 1369 cells/μl, and 1825 cells/μl (before onset vs. during infection: p = 0.0005). There was no significant change in CD4+ cell, CD8+ cell and total lymphocyte counts between those before symptom onset and after recovery. A transient decrease in CD4+ cell, CD8+ cell and lymphocyte counts were observed during the acute phase in both influenza infection and COVID‐19 in PLWH. As a result, the CD4+/CD8+ ratio did not change in both infections. Our result indicates that the lymphocyte depletion of COVID‐19 can be caused by the decrease in the total number of T cells rather than the alteration of the T cell differentiation, and it is possible that the same phenomenon occurs in the seasonal influenza infection. T cell counts are rarely tested for COVID‐19 in non‐HIV infected individuals. Considering that transient lymphocytopenia with COVID‐19 also occurs in non‐HIV‐infected individuals, however, transient CD4+ cell and CD8+ cell depletion in both influenza infection and COVID‐19 could occur in non‐HIV‐infected individuals. Little has been known about the transition of T cell count in seasonal influenza virus infection, as most of them are confined to mild illness, and lymphocyte count and T cell subsets are rarely tested. Acute viral infections can cause accelerated lymphocyte consumption, decreased lymphocyte migration in the spleen or lymph nodes, or increased migration of lymphocytes to organs such as the lungs and upper respiratory tract. Transient T cell depletion can also occur with other viral infections, and further research is needed for assessing the clinical impact of this transient change.

AUTHOR CONTRIBUTIONS

Eisuke Adachi: carried out the project and drafted the manuscript. Eisuke Adachi, Makoto Saito, Hiroyuki Nagai, Michiko Koga, Takeya Tsutsumi, and Hiroshi Yotsuyanagi: were responsible for the clinical management of the patient. Kazuhiko Ikeuchi: contributed to data collections. Makoto Saito and Hiroshi Yotsuyanagi: revised the manuscript. All authors approved the final manuscript.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

ETHICS STATEMENT

Ethics approval was granted by the ethics board of the Institute of Medical Science, University of Tokyo (2020‐5‐0420).
  6 in total

1.  Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.

Authors:  Christian Hoffmann; José L Casado; Georg Härter; Pilar Vizcarra; Ana Moreno; Dario Cattaneo; Paola Meraviglia; Christoph D Spinner; Farhad Schabaz; Stephan Grunwald; Cristina Gervasoni
Journal:  HIV Med       Date:  2020-12-27       Impact factor: 3.180

2.  T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019.

Authors:  Mei Jiang; Yang Guo; Qing Luo; ZiKun Huang; Rui Zhao; ShuYuan Liu; AiPing Le; JunMing Li; LaGen Wan
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 5.226

3.  Viral and host factors related to the clinical outcome of COVID-19.

Authors:  Xiaonan Zhang; Yun Tan; Yun Ling; Gang Lu; Feng Liu; Zhigang Yi; Xiaofang Jia; Min Wu; Bisheng Shi; Shuibao Xu; Jun Chen; Wei Wang; Bing Chen; Lu Jiang; Shuting Yu; Jing Lu; Jinzeng Wang; Mingzhu Xu; Zhenghong Yuan; Qin Zhang; Xinxin Zhang; Guoping Zhao; Shengyue Wang; Saijuan Chen; Hongzhou Lu
Journal:  Nature       Date:  2020-05-20       Impact factor: 69.504

Review 4.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

5.  Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components.

Authors:  Om Prakash Choudhary; Indraj Singh
Journal:  Travel Med Infect Dis       Date:  2020-11-10       Impact factor: 6.211

6.  Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome.

Authors:  Wei Cui; Ying Fan; Wei Wu; Feng Zhang; Jun-ying Wang; An-ping Ni
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

  6 in total
  1 in total

Review 1.  RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.

Authors:  Chandrasekharan Rajalekshmi Dhanya; Aswathy Shailaja; Aarcha Shanmugha Mary; Sumodan Padikkala Kandiyil; Ambili Savithri; Vishnu Sasidharan Lathakumari; Jayakrishnan Therthala Veettil; Jiji Joseph Vandanamthadathil; Maya Madhavan
Journal:  Pathogens       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.